ArticleNature materials2026
Radioisotope-mimetic molecular afterglow probe for downregulated cancer biomarker imaging.
Article in Nature materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular afterglow imaging is a biomedical modality with high sensitivity and specificity. However, due to the short half-lives of existing afterglow agents, longitudinal imaging often requires multiple on-site reinductions. Here we report a probe with month-long afterglow luminescence and the ability to target a downregulated liver tumour biomarker. This downregulated-biomarker-activatable afterglow probe (DROP) operates through a self-sustainable photoenergy cycling reaction, during which afterglow resonance energy transfer re-excites the afterglow initiator to regenerate singlet oxygen. This process initiates new afterglow resonance energy transfer cycles, extending the afterglow duration to over 40 days. The long afterglow of DROP enables in vivo imaging over 8 h with a single light preinduction, mimicking the imaging process of radioisotopes. Moreover, DROP quickly becomes inactive in healthy liver tissues due to cytochrome P450 enzyme activity, detecting and delineating tumours as small as 1 mm in diameter for complete surgical resection in both murine and rabbit models. Overall, we provide fundamental guidelines to develop radioisotope-mimetic afterglow luminescence probes and highlight the targeting of downregulated biomarkers as a promising approach in cancer theranostics.
Indexed as
Identifiers
41714700What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.